1. Clinical & Scientific Overview
Liquid Paraffin Emulsions (TIP-MED-000298, Reference Code [5.17]-C28) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Bulk-Forming Soluble Fibre Laxative & Faecal Lubricant/Osmotic Combinations (OTC / Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [5.17] (Ispaghula Husk (Psyllium) & Liquid Paraffin Emulsions). Representative Indian Market Examples (Edition 2.7 Ch 05 [5.17], p. 68): Ispaghula: Sat-Isabgol, Fybogel, Naturolax, Fikul. Emulsions: Cremaffin (Milk of Magnesia + Liquid Paraffin), Cremaffin Plus (+ Sodium Picosulfate) — Strengths & Dosage Forms: Ispaghula Husk Powder/Granules: 3.5 g – 5 g per sachet/scoop. Emulsions: 15 mL oral suspension
Ispaghula Husk Powder/Granules: 3.5 g – 5 g per sachet/scoop. Emulsions: 15 mL oral suspension
3. Mechanism of Action & Pharmacodynamics
Bulk-Forming Soluble Fibre Laxative & Faecal Lubricant/Osmotic Combinations (OTC / Schedule H) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Bulk-Forming Soluble Fibre Laxative & Faecal Lubricant/Osmotic Combinations (OTC / Schedule H) for Chronic idiopathic constipation, constipation in pregnancy, irritable bowel syndrome (IBS), haemorrhoids, and post-anorectal surgery (anal fissure/fistula) to prevent straining.
4. Therapeutic Indications & Evidence-Supported Uses
- Chronic idiopathic constipation, constipation in pregnancy, irritable bowel syndrome (IBS), haemorrhoids, and post-anorectal surgery (anal fissure/fistula) to prevent straining
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Ispaghula: 1 sachet/scoop (3.5–5 g) stirred briskly in 250 mL water OD–BD after meals. Liquid Paraffin + Mg(OH)2 Emulsion: 10–15 mL PO at bedtime for short-term relief (3–5 days)
Administration & Meal Timing: CRITICAL FLUID RULE FOR ISPAGHULA: Stir powder into a FULL GLASS (250 mL) of water and drink IMMEDIATELY before it gels, followed by another half glass of water — taking dry powder without water causes oesophageal or intestinal obstruction! Do NOT take immediately before going to sleep | Ispaghula: After Breakfast &/or Dinner (at least 1 hour before bedtime). Emulsion: Bedtime
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [5.17].
Renal: Ispaghula is safe in CKD; AVOID Magnesium Hydroxide-containing emulsions (Cremaffin) in CKD Stage 4–5 (use Lactulose or PEG 3350 instead!). Hepatic: Safe
Renal: Ispaghula is safe in CKD; AVOID Magnesium Hydroxide-containing emulsions (Cremaffin) in CKD Stage 4–5 (use Lactulose or PEG 3350 instead!). Hepatic: Safe
Renal: Ispaghula is safe in CKD; AVOID Magnesium Hydroxide-containing emulsions (Cremaffin) in CKD Stage 4–5 (use Lactulose or PEG 3350 instead!). Hepatic: Safe
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in suspected intestinal obstruction, faecal impaction, dysphagia, and acute surgical abdomen. Avoid Liquid Paraffin in bedridden elderly or neurological dysphagia (risk of fatal lipoid aspiration pneumonia!)
Key Clinical Precautions: Renal: Ispaghula is safe in CKD; AVOID Magnesium Hydroxide-containing emulsions (Cremaffin) in CKD Stage 4–5 (use Lactulose or PEG 3350 instead!). Hepatic: Safe
8. Adverse Effects Profile
- Transient flatulence and abdominal fullness (Ispaghula); anal seepage/pruritus (Liquid Paraffin)
- Oesophageal/bowel obstruction (if Ispaghula taken with insufficient water), lipoid pneumonia (if Liquid Paraffin aspirated), hypermagnesaemia in CKD (from Milk of Magnesia in Cremaffin!)
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Ispaghula traps oral drugs in its mucilage matrix — separate Ispaghula by >=1–2 hours from Levothyroxine, Digoxin, Warfarin, Lithium, and Carbamazepine!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [5.17].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Stir Ispaghula into a full 250 mL glass of water and drink immediately (never swallow dry powder!); wait at least 1 hour before lying down; space 2 hours away from other tablets
- Meal & Clock Timing Instruction: CRITICAL FLUID RULE FOR ISPAGHULA: Stir powder into a FULL GLASS (250 mL) of water and drink IMMEDIATELY before it gels, followed by another half glass of water — taking dry powder without water causes oesophageal or intestinal obstruction! Do NOT take immediately before going to sleep (Ispaghula: After Breakfast &/or Dinner (at least 1 hour before bedtime). Emulsion: Bedtime)
- Missed Dose Protocol: Skip if forgotten; never take Ispaghula right at bedtime
- Geriatric Dispensing Pearl: In frail or bedridden older adults with swallowing difficulty, avoid Liquid Paraffin emulsions and Magnesium laxatives in CKD — prefer PEG 3350 or Lactulose
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ispaghula Husk Powder/Granules: 3.5 g – 5 g per sachet/scoop. Emulsions: 15 mL oral suspension
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [5.2] Esomeprazole Magnesium Trihydrate — Proton Pump Inhibitor (S-Isomer of Omeprazole)
- [5.3] Omeprazole — First-Generation Proton Pump Inhibitor (Racemic Benzimidazole Der
- [5.4] Rabeprazole Sodium — Proton Pump Inhibitor (Non-Enzymatically Metabolised Benzimidazol
- [5.5] Famotidine — Histamine H2-Receptor Antagonist (H2 Blocker)
